April 2, 2012 — Approval for the new 23-mg dose of the Alzheimer's disease (AD) drug donepezil (Aricept, Eisai) "breached the FDA's own regulatory standard" and has led to "incomplete and distorted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results